This new interactive feature allows you to review the treatment options for low-risk primary myelofibrosis, share your approach to determining the highest value treatment, and help to build a consensus clinical pathway for this disease.

Accredited CME from Imedex

Newly emerging evidence is informing best care for patients with polycythemia vera (PV). Not only are recently updated diagnostic criteria available for PV, but better ways to assess risk of thrombosis and disease progression are being discovered.
Ongoing discoveries continue to lead to preclinical breakthroughs and clinical advances in how MPN and MDS are diagnosed and treated.
Advances in both preclinical science and clinical management practices continue to change how MPN and MDS are diagnosed and treated.

Interviews

Journal of Clinical Pathways spoke with Christoph Menzel, PhD, Director of Global Product Management MDx, Qiagen, about the implications of the ipsogen JAK2 assay FDA approval and the importance of JAK2 testing to support treatment decision-making for MPNs.
Jim Epstein, MD, and David Steensma, MD, highlight key strategies in the management of patients with leukemia or myelodysplastic syndromes.

News

Contrary to initial reports, romiplostim treatment of thrombocytopenia does not appear to increase the risk of progression from myelodysplastic syndrome to acute myeloid leukemia.
Haplo/cord reduced-intensity allogeneic transplantation yields similar outcomes as HLA-matched unrelated donor cells for older patients with MDS.
The US Food and Drug Administration has approved the ipsogen JAK2 assay for use in the diagnosis of all myeloproliferative neoplasms.
Myeloproliferative neoplasms are associated with an increased risk for arterial and venous thrombosis, according to a population-based study of Swedish registries.

Quiz

Updated NCCN guidelines for myeloproliferative neoplasms offer which of the following options for the management of myelofibrosis-associated anemia?

Resources

This new interactive feature allows you to review the treatment options for low-risk primary myelofibrosis, share your approach to determining the highest value treatment, and help to build a consensus clinical pathway for this disease.
The National Comprehensive Cancer Network has released updates to their guidelines for myeloproliferative neoplasms, including management suggestions for related disorders and testing options.
Subscribe to Myeloproliferative Neoplasms